BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: AlQahtani M, Kumar N, Aljawder D, Abdulrahman A, Alnashaba F, Fayyad MA, Alshaikh F, Alsahaf F, Saeed S, Almahroos A, Abdulrahim Z, Otoom S, Atkin SL. Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease. Sci Rep 2022;12:4925. [PMID: 35322077 DOI: 10.1038/s41598-022-08794-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang P, Liu C, Wang Y, Yu H. Advanced Pedestrian State Sensing Method for Automated Patrol Vehicle Based on Multi-Sensor Fusion. Sensors 2022;22:4807. [DOI: 10.3390/s22134807] [Reference Citation Analysis]
2 Rattanaumpawan P, Jirajariyavej S, Lerdlamyong K, Palavutitotai N, Saiyarin J. Real-World Effectiveness and Optimal Dosage of Favipiravir for Treatment of COVID-19: Results from a Multicenter Observational Study in Thailand. Antibiotics (Basel) 2022;11:805. [PMID: 35740211 DOI: 10.3390/antibiotics11060805] [Reference Citation Analysis]
3 Stalinskaya AL, Martynenko NV, Shulgau ZT, Shustov AV, Keyer VV, Kulakov IV. Synthesis and Antiviral Properties against SARS-CoV-2 of Epoxybenzooxocino[4,3-b]Pyridine Derivatives. Molecules 2022;27:3701. [PMID: 35744830 DOI: 10.3390/molecules27123701] [Reference Citation Analysis]
4 Mir I, Aamir S, Shah SRH, Shahid M, Amin I, Afzal S, Nawaz A, Khan MU, Idrees M. Immune-related therapeutics: an update on antiviral drugs and vaccines to tackle the COVID-19 pandemic. PHRP 2022;13:84-100. [DOI: 10.24171/j.phrp.2022.0024] [Reference Citation Analysis]